Clinical Trial Update: Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer [Phase 4]

View source ↗

Summary

A phase 4 trial update describing ramucirumab in combination with nab-paclitaxel, lobaplatin, and S-1 as neoadjuvant therapy for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Lobaplatin (lobaplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Ramucirumab (ramucirumab)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Yang Jianjun, PhD | Conditions: Advanced Gastric Cancer | Phase 4 | Status: UNKNOWN